D. Loirat

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 795 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo, A. Bardia, F. Marmé et al. · Annals of Oncology · 2022 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, Fabrice André, Anthony Gonçalvès et al. · Annals of Oncology · 2024 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17